Free Access
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1183 - 1188
Section III - Un futur en développement
Published online 15 December 2009
  1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  2. Anticorps monoclonaux pour usage humain, monographie 2031. Pharmeuropa 2009; 21 : 104–8. [Google Scholar]
  3. Stebbings R, Findlay L, Edwards C, et al. “Cytokine storm” in the phase 1 trial of monoclonal antibody TGN1412 - better understanding the causes to improve pre-clinical testing of immunotherapeutics. J Immunol 2007; 179 : 3325–31. [Google Scholar]
  4. Longstaff C. Personal communication. [Google Scholar]
  5. Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies Nat Biotechnol 2008; 26 : 985–90. [Google Scholar]
  6. Beck A, Lyer H, Reichert JM. European Medicines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). mAbs-Landes Bioscience 2009; 1 : 394–416. ( [Google Scholar]
  7. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23 : 1073–8. [Google Scholar]
  8. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16 : 2825–33. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.